2 recruiting, 1 active not recruiting, 1 unknown. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Recruiting 2, Active not recruiting 1, Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Stage III Breast Cancer: new trials by email Literature Review of Stage III Breast Cancer trials Research Report on Stage III Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Postoperative Radiotherapy in Breast Cancer- Concurrent or Sequential With Chemotherapy Chemoradiation - Invasive Breast Cancer, Stage III Breast Cancer | Phase 3 | Recruiting | Dr. Tabassum Wadasadawala | 858 | 2024-05-14 | 2025-04-13 |
| Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) Elacestrant, Tamoxifen, Letrozole 2.5mg - ER-positive Breast Cancer, HER2-negative Breast Cancer | Phase 3 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 220 | 2023-12-15 | 2026-10-07 |
| A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer docetaxel, epirubicin and cyclophosphamide, docetaxel, epirubicin and cyclophosphamide plus endostar - Stage III Breast Cancer | Phase 2 / Phase 3 | Unknown | Hebei Medical University Fourth Hospital | 300 | 2019-08-01 | 2019-08-09 |
| Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy Capecitabine, Carboplatin, Cisplatin - Estrogen Receptor Negative, HER2/Neu Negative | Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 415 | 2015-10-20 | 2026-11-02 |
Breast Neoplasms (4) · Triple Negative Breast Neoplasms (1)
Breast Diseases (4) · Neoplasms (4) · Neoplasms by Site (4) · Skin Diseases (4) · Skin and Connective Tissue Diseases (4)
Anastrozole (1) · Capecitabine (1) · Carboplatin (1) · Chemoradiotherapy (1) · Cisplatin (1) · Cyclophosphamide (1) · Docetaxel (1) · Epirubicin (1) · Letrozole (1) · Tamoxifen (1) · elacestrant (1) · endostar protein (1) · exemestane (1)
Dr. Tabassum Wadasadawala (1) · ECOG-ACRIN Cancer Research Group (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Hebei Medical University Fourth Hospital (1)
Belgium (1) · China (1) · Cyprus (1) · France (1) · Germany (1) · Greece (1) · India (1) · Ireland (1) · Italy (1) · Netherlands (1) · Portugal (1) · South Africa (1) · Spain (1) · Sweden (1) · Switzerland (1)
Emmanouil Saloustros (1) · Ingrid Mayer (1) · Michail Ignatiadis (1)
U10CA180820 (1), U24CA196172 (1)